Delivery Order SPE2DB24D2205-SPE2DB25FEGVX
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,278.36 to AmerisourceBergen Drug Corp for Shingrix vial kits on July 16, 2025, with completion targeted for July 17, 2025. This competitively awarded, firm fixed price delivery order represents a small-value pharmaceutical procurement executed through AmerisourceBergen's existing contract vehicle with DLA. The work will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Shingrix is a recombinant...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits valued at $8,769.12, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,278.36 to AmerisourceBergen Drug Corp for Shingrix vial kits on September 19, 2025, with completion targeted for September 22, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,139.18 to AmerisourceBergen Drug Corp for Shingrix vial kits on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $10,533.22 to AmerisourceBergen Drug Corp for Shingrix vial kits on September 11, 2025, with completion scheduled for September 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. Shingrix is a recombinant zoster vaccine used for prevention of herpes zoster (shingles) and post-herpetic neuralgia in...
- The Defense Logistics Agency awarded a $15,032.22 delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits, with an ultimate completion date of April 25, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is listed as Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $14,012.49 delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits, with an ultimate completion date of August 18, 2025. This contract represents a firm fixed-price delivery order issued under a competitive procurement with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Shingrix is a recombinant zoster vaccine used for the prevention of herpes zoster (shingles) in...
- The Defense Logistics Agency awarded a $11,391.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits, with a completion date of June 6, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion vehicle designated SPE2DX and running through December 2026. The order will be fulfilled from AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $4,779.14 to AmerisourceBergen Drug Corp for Shingrix vial kits, with a completion date of July 22, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The work will be performed at the contractor's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $4,206.70 to AmerisourceBergen Drug Corp for Shingrix vial kits, with a completion date of March 27, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. Shingrix is a recombinant zoster vaccine indicated for the prevention of herpes zoster (shingles) and is a critical immunization product for military and veteran...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEGVXDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,456.06 to AmerisourceBergen Drug Corp for Shingrix vial kits on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitive award, executed under firm fixed pricing, represents a child order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The place of performance is listed as the vendor's corporate office in Conshohocken, Pennsylvania. Shingrix is a recombinant zoster vaccine indicated for the prevention of herpes zoster (shingles) and is a standard pharmaceutical supply for military and veteran healthcare systems. This delivery order reflects DLA's ongoing procurement of vaccines and medical supplies through AmerisourceBergen's prime vendor global pharmaceutical support vehicle, which enables the agency to maintain consistent access to a comprehensive range of pharmaceutical products across multiple therapeutic domains to support military healthcare programs worldwide. The non-set-aside designation indicates this award was made through open competition, demonstrating AmerisourceBergen's continued qualification as a critical pharmaceutical distributor for federal medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 8/27/25 |